HIV-1 Nef Promotes Endocytosis of Cell Surface MHC Class II Molecules via a Constitutive Pathway

Ashutosh Chaudhry, Divya Anna Verghese, Suman Ranjan Das, Shahid Jameel, Anna George, Vineeta Bal, Satyajit Mayor and Satyajit Rath

J Immunol 2009; 183:2415-2424; Prepublished online 20 July 2009;
doi: 10.4049/jimmunol.0804014
http://www.jimmunol.org/content/183/4/2415

References
This article cites 44 articles, 23 of which you can access for free at:
http://www.jimmunol.org/content/183/4/2415.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

Errata
An erratum has been published regarding this article. Please see next page or:
/content/183/11/7611.1.full.pdf
HIV-1 Nef Promotes Endocytosis of Cell Surface MHC Class II Molecules via a Constitutive Pathway

Ashutosh Chaudhry, Divya Anna Verghese, Suman Ranjan Das, Shahid Jameel, Anna George, Vineeta Bal, Satyajit Mayor, and Satyajit Rath

HIV-1 Nef has been reported to disrupt MHC class II (MHCII)-mediated Ag presentation by a dual strategy that comprises a reduction in cell surface levels of peptide-loaded mature MHCII molecules and a up-regulation of immature MHCII molecules. We show that Nef achieves relocation of MHCII away from the cell surface in monocytic cells by both delaying its transport to the cell surface and by accelerating endocytic removal of cell surface MHCII to a lysosomal compartment. Nef-induced MHCII endocytosis is cholesterol-sensitive but clathrin- and dynamin-independent. Internalized MHCII molecules traverse the early endosomal system and colocalize with pinocytic cargo before reaching lysosomes. Nef-triggered MHCII endocytosis requires Rab5 activity and lys function, whereas lysosomal trafficking of internalized MHCII molecules requires Rab7 activity. We further show that a similar pathway can remove peptide-MHCII complexes from the surface of monocytic cells not expressing Nef. Our data suggest that Nef uses mechanisms involved in normal MHCII recycling and turnover to mediate the delivery of cell surface MHCII to a lysosomal destination. Thus, Nef-mediated endocytosis of MHCII provides a novel perspective on the regulation of normal MHCII trafficking. The Journal of Immunology, 2009, 183: 2415–2424.

The nonstructural Nef protein of HIV-1 is a critical contributor to viral pathogenicity in a variety of ways (1–4). Nef is a conglomerate of protein-protein interaction modules, intersecting multiple cellular trafficking, and signaling pathways (5, 6). Nef affects the expression of a variety of molecules on the APC surface that are critical in the generation of immune responses. Notably Nef mediates the down-regulation of cell surface levels of both classes of MHC molecules, as well as cell surface levels of the immune costimulatory molecules CD80 and CD86 (7–9).

Viruses that fuse at the plasma membrane and release most of their proteins directly into the cytosol, as well as viruses that establish persistent latent infections and constitutively express low levels of cytosolic Ags, have been found to be effectively detected by the presentation of cytosolic viral epitopes on MHC class II (MHCII) by (10). Viruses use multiple strategies to circumvent MHCII-dependent immunity, a common one being alteration in the cellular trafficking of MHCII (11). MHCII molecules extensively negotiate the endolysosomal system. Nascent MHCII molecules in complex with the invariant chain (Ii) exit the endoplasmic reticulum and move through the Golgi apparatus before intersecting the endocytic system in specialized MHCII peptide-loading compartments variously termed MIIIC (MHCII-enriched compartment) or CIIV (class II vesicles) (12, 13). These compartments are thought to be a collection of late endocytic or lysosomal compartments containing the necessary components for Ii degradation and efficient peptide loading on MHCII before its egress to the cell surface (13, 14). Constitutive endocytosis and recycling of cell surface MHCII have also been well documented (15) and are considered a pathway for the presentation of some Ags (16), although the molecular regulators of such trafficking are not yet well understood. The extensive dependence of MHCII on the endocytic system for its function offers a potential target for viral subversion.

Nef has been reported to inhibit MHCII-dependent Ag presentation by the reduction of cell surface levels of mature MHCII and the up-regulation of immature MHCII, which are functionally incompetent because of persistent association with the Ii (9). In the presence of Nef, mature MHCII molecules are reduced at the cell surface and are found at high levels in intracellular lysosomal compartments. The delivery of immature MHCII to the endolysosomal compartment is also impaired, resulting in reduced Ii degradation (17). Mutational analysis suggests that these mechanisms are well conserved among nef alleles (18).

Endocytic mechanisms involve a variety of internalization pathways with variable dependence on factors such as coat proteins like clathrin and caveolin, levels of membrane cholesterol, and scissoring agents such as dynamin (Dyn) and small GTPases of the Rho family (19, 20). This potentially provides Nef with an assortment of molecular adaptors that can be subverted. Nef is known to affect many of these endocytic programs to modulate the expression of several cell surface molecules (4).

On this background, we have examined the process by which Nef mediates the redistribution of MHCII in human monocytic cells. The Journal of Immunology, 2009, 183: 2415–2424.

Received for publication December 9, 2008. Accepted for publication June 2, 2009.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported in part by grants from the Departments of Science and Technology, and Biotechnology, Government of India (to A.G., S.R., and V.B.). S.R.D. was supported by a fellowship from the Council for Scientific and Industrial Research, Government of India. National Institute of Immunology and International Centre for Genetic Engineering and Biotechnology are supported by the Department of Biotechnology, Government of India.

Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0804014

Abbreviations used in this paper: MHCII, MHC class II; Bg, beige; BMDM, bone marrow-derived macrophage; C/A, constitutively active; DN, dominant negative; Dyn, dynamin; eGFP, enhanced GFP; Ii, invariant chain; MBCD, methyl-β-cyclodextrin; MHCII, MHC class II; NA, numerical aperture; PIK, phosphatidylinositol kinase; pMHCII, peptide-MHCII complex; sh-Dyn, short interfering RNA for Dyn-2; Tf, transferrin; Wm, wortmannin; WT, wild type.

*National Institute of Immunology, New Delhi, India; †International Centre for Genetic Engineering and Biotechnology, New Delhi, India; and ‡National Centre for Biological Sciences, Bangalore, India.

Address correspondence and reprint requests to Dr. Satyajit Rath, National Institute of Immunology, Aruna Asaf Ali Road, New Delhi 110067, India. E-mail address: satyajit@nih.res.in

© 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00
cells. We find that Nef triggers MHCII internalization in a cho-

leroster-dependent but clathrin- and Dyn-independent manner that closely mimics the constitutive endocytosis of peptide-MHCII molecules. These findings indicate that Nef exploits a constitutive endocytic program to subvert surface MHCII expression in HIV-

infected cells.

Materials and Methods

Plasmids and reagents

The F2-nef gene from an Indian HIV-1 subtype C primary isolate cloned into pIRE62-EGFP or pEGFP-N3 has been described earlier (7). The K44A dominant negative (DN)-Dyn construct was obtained from Dr. M. McNiven (Mayo Clinic, Rochester, MN), the DN Eps15 construct from Dr. A. Dautry-Varsat (Institut Pasteur, Paris, France), the Rab11 constructs from Dr. N. Bunnett (University of California, San Francisco, CA), and the Rab5- and Rab7-related constructs from Dr. M. Zerial (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany) for use as described earlier (21).

The following reagents were used: fluorophore-labeled dextran (tetramethylrhodamine-dextran) and transferrin (Tf) (Molecular Probes), mAbs Y-Ae (anti-Ea52–68-H-2Aβ) and Y3P (anti-H-2Aβ) have been described previously (22). Labeled Alexa Fluor dyes (Molecular Probes). The mAbs Y-Ae (anti-Ea52–68-H-2Aβ) and Y3P (anti-H-2Aβ) have been described previously (22). Labeled secondary detection reagents used included goat anti-mouse IgG (Fc)-PE, donkey anti-rat IgG (Fc)-PE (Jackson ImmunolResearch Laboratories), streptavidin-PE, streptavidin-CyChrome, and streptavidin-PE-Texas Red (BD Pharmingen).

Cells and transfection

BMC-2 cells were maintained in Click’s medium with FCS, 2-ME, t-glutamine, and antibiotics. U937 cells were maintained in RPMI 1640 me-
dium with FCS and antibiotics. Cells were kept in 0.5 μg/ml LPS overnight before use to enhance MHC levels. Primary marine monocytotes were grown from mouse bone marrow by culturing nonadherent mouse bone marrow cells with M-CSF (30% L-sp2 fibroblast-conditioned medium as M-CSF source) for 7 days, with periodic growth factor replenishment. Primary human monocytotes were grown from PBMC by culturing them with rM-CSF (100 U/ml; Sigma-Aldrich) for 3 days, and live cells were used for infection in the continuing presence of the growth factor. Transfec-
tions of cell lines and mouse primary cells were done using FuGENE 6 (Roche) or Effectene (Qiagen), according to the manufacturer’s:

col. Primary human monocytotes were transfected by nucleoporation according to the manufacturer’s protocol (Amaza). Briefly, 1 x 106 cells were resuspended in Nucleofector solution following by the addition of 4–6 μg of plasmid DNA and cells were nucleoporated following manufacturer’s instructions (Amaza).

Antigens

A recombinant fusion protein (GST-Ea52–68-Myc) consisting of GST, aa residues 52–68 of the mouse H-2Ea sequence (Ea52–68), and the oligopep-
tide sequence of the c-Myc protein was made in Escherichia coli from the plasmid pGEX-2T as described previously (22).

Immunofluorescence microscopy and image processing

Cells were fixed with 4% paraformaldehyde for 20 min at 37°C and per-
meabilized using 0.3% Tween 20 or 0.03% saponin in PBS for 20 min at ambient temperature. They were then blocked with 2 mg/ml BSA in PBS before incubation with Abs in the same medium. Rabbit and mouse pri-
mary Abs were detected using fluorophore-labeled, Fc-specific anti-rabbit IgG or anti-mouse IgG.

Confocal and wide field microscopy

Confocal imaging was conducted on a Zeiss LSM510 confocal microscope (Zeiss) equipped with factory set dichroics and an argon-krypton laser using the Zeiss software with a step size of 0.2 µm and a digital zoom of 3.5 corresponding to a pixel size of 0.10 µm was used. Pinhole size was kept constant at 272 U (optical section, <2 µm; airy units, <3), and 12 bit images were collected at ×63 original magnification and a 1.45 numerical aperture (NA) objective.

Optimized dichroics, excitation, and emission filters were used as de-
scribed (23). Fluorophores were imaged for multilabel analysis us-

Nef SUBVERTS CONSTITUTIVE MHCII ENDOCYTOSIS

Quantitative colocalization analysis

Colocalization between internalized vesicles and endocytic markers was quantified using two types of software, MultiSpots and MultiColloc (21, 24), variations of the custom-developed software, Spots and Coloc, respec-
tively, as described previously (21, 25–28). The criteria outlined below were applied to images obtained from U937 cells labeled with Abs against Rab5, Ea51, Ea7, Rab7, Rab11, and LAMP1 or pulsed with the endocytic tracers Tf and dextran for 10 min at 37°C. High-resolution images of cells labeled with endocytic tracers were obtained using a ×60 original magnifi-
cation, 1.4 NA objective on a wide-field microscope at a pixel resolution of 0.15μm/pixel. The images were corrected for background fluorescence using the “produce background correction” image procedure in Metamorph image analysis software with the following parameters suitable for pro-

ducing a local background image while at the same time preserving the intensity of the endosomes (box size, 30 × 30 pixels; subsample ratio, 10; percent, 0.2).

The background corrected images were then processed through Multi-

Spots to identify endosomes using parameters defined by pixels above a threshold (set by inspection for each image) and area (minimum, 3 pixel; maximum, no upper limit). A trimming procedure was applied to remove non-

infected cells and segregate individual endosomes based on the inclusion of pixels with intensities >0.3 of maximal intensity within a unit of connected pixels having an intensity greater than that of the set threshold. This was achieved by an iterative procedure using a step size (0.01) for each iteration with limits for the number of iterations of the trimming procedure. The resultant image contains a set of identified “spots or endosomes” quantified in terms of net intensity per spot and total pixel area per spot.

The two “spotted” images of different fluorophore-labeled markers were matched up against each other to identify the endosomes wherein the two molecules were colocalized. Endosomes in a tracer image (e.g., MHCII-associated endosomes) were compared with endosomes in a reference im-
age (e.g., Rab11-containing endosomes) using MultiColoc, and endosomes with >50% area overlap were considered to be colocalized. The resultant image displayed all of the spots that were colocalized using a particular “tracer-reference” image pair.

Cell outlines were drawn based on the phase contrast image of the cell, and the net intensity of each fluorophore per cell was calculated in the spotted as well as the colocalized images using procedures in Metamorph. The percentage of colocalization was then calculated from the ratio of the net intensity within a cell in the MHCII with the appropriate Rab5/Ea51/

Rab7/endocytic marker MultiColoc image to the net spot intensity in the same cell in the MHCII spots image. The maximum extent of colocal-

ization obtained by this method is 90% for the colocalization of cointer-

nalized Alexa Fluor 568-Tf and Alexa Fluor 647-Tf in the same cell. The percentage of colocalization is represented as a mean and SEM obtained from three independent experiments with a minimum of 50 cells per experiment. All images were processed for output purposes using Adobe Photoshop software. Digital color assignments were made for each fluor-

ophore so as to provide maximum visual contrast.

Cell labeling and other treatments

U937 cells were transfected with various plasmids and surface labeled 12 h later with either biotinylated or primary-labeled anti-MHCII Ab on ice for 30 min. Cells were then warmed to 37°C and chased for varying lengths of time. To visualize the endosomal distribution of the fluorescent tracers, the cell surface label (fluorophore-labeled Tf or anti-MHCII) was removed by using a combination of low pH and high pH buffers (ascorbate buffer (pH 4.5), 160 mM sodium ascorbate, 40 mM ascorbic acid, 1 mM MgCl2, and 1 mM CaCl2).

Flow cytometry

Cells were stained with primary and secondary reagents on ice for 30 min, with appropriate control. For intracellular staining, cells were permeabilized with 0.03% saponin. Stained cells were analyzed on a BD LSR flow cytometer (BD Biosciences) and data were analyzed using FlowJo software (Tree Star). All data shown are representative of 3–5 independent experiments.
Figure 1. HIV-1 Nef reduces cell surface but not total MHCII levels on human and mouse myeloid cells. A, U937 or BMC-2 cells were transfected to express either eGFP alone (black lines) or Nef and eGFP (red lines) and stained 24 h later for MHCII either before (surface) or after (total) permeabilization. Histograms show MHCII levels on eGFP-gated cells. B, U937 cells were either mock infected (black line) or infected with WT HIV-1 (NL4-3; blue line) or with nef-deleted NL4-3 virus (red line) and stained for cell surface MHCII and intracellular HIV-1 p24 protein 2 days later. Histograms show surface MHCII levels on p24-gated cells. C, Primary human monocytes were transfected to express either eGFP alone (black lines) or Nef and eGFP (blue lines) and stained 24 h later for cell surface MHCII. Histograms show MHCII levels on eGFP-gated cells. D, Primary human monocytes were either mock infected (black line) or infected with WT HIV-1 (NL4-3 Ada; red line) or nef-deleted NL4-3 Ada virus (blue line) and stained for cell surface MHCII and intracellular HIV-1 p24 protein 2 days later. Histograms in the left panel show p24 levels in infected cells and the p24 gate used. Histograms in the right panel show surface MHCII levels on p24-gated cells. E, U937 cells transfected to express either eGFP alone (black lines) or Nef and eGFP (red lines) were stained 12 h after transfection with anti-MHCII-biotin or anti-CD80-biotin, and held at either 4°C or 37°C as indicated. Cells were then stained with the same anti-MHCII or anti-CD80 mAbs conjugated to PE to detect newly expressed molecules. Histograms show levels of new MHCII or CD80 molecules delivered to the cell surface as detected by PE-labeled mAbs in eGFP-gated cells. Gray curves in all panels represent isotype controls. Data are representative of 3–5 independent experiments.

Viruses and infection

HIV-1 viral stocks were generated by electroporation of HeLa cells with the infectious molecular clones pNL4-3 and pNL4-3 FS Nef (gifts from H. Gottlinger, University of Massachusetts Medical School, Worcester, MA) or pNL-4-3 ADA and pNL4-3 ADA-Nef (gifts from M. Stevenson, University of Massachusetts Medical School, Worcester, MA). Virus stocks were harvested 72 h later and filter sterilized. U937 cells or primary human monocytes were serum starved for 1 h before infection. For each infection, 1 x 106 cells were infected with 100,000–200,000 cpm of reverse-transcriptase counts of virus. After 4 h of adsorption, cells were washed and incubated for 48 h before being stained for surface MHCII and intracellular p24 Gag protein.

Animals

C57BL/6 and bg/bg mice were obtained from The Jackson Laboratory and bred in the small animal facility of the National Institute of Immunology (New Delhi, India). All animal experiments were done under the approval of the Institutional Animal Ethics Committee.

Results

HIV-1 Nef reduces cell surface MHCII levels in myeloid cells

A wild-type (WT) nef gene (F2-nef) cloned from an Indian clinical isolate (7) was transfected into the human monocytic U937 cell line. Cell surface MHCII levels were reduced 5- to 10-fold at 48 h post-transfection (Fig. 1A). This was accompanied by a reduction in the levels of MHC class I (MHCII), CD80, and CD86 as reported earlier (7), whereas levels of other molecules such as the Tfi receptor did not exhibit any changes (Ref. 7 and data not shown). The total cellular levels of MHCII, however, as measured by staining postpermeabilization, were unaltered (Fig. 1A). Furthermore, Nef expression led to a similar reduction of cell surface MHCII levels in the murine monocytic cell line BMC-2, although there was no reduction in the total cellular levels of MHCII postpermeabilization (Fig. 1A). Similar effects were found on primary mouse bone marrow-derived dendritic cells and monocytes as well (data not shown). MHCII levels were also dramatically reduced on U937 monocyctic cells infected with WT HIV-1, in contrast to cells infected with Nef-deficient HIV-1 (Fig. 1B). The modest residual reduction in surface MHCII levels in the cells infected with Nef-deficient HIV-1 could be the effect of the Vpu protein of HIV-1, which has previously been shown to cause such a modest reduction in cell surface MHCII levels in monocytic cells (29).

We next tested whether the reduction of cell surface MHCII levels observed in Nef-expressing U937 cells or in mouse monocytic cells was also observed in primary human monocytes. Human primary monocyte cultures were transfected to express enhanced GFP (eGFP) alone or Nef and eGFP. Expression of Nef in human primary monocytes also led to a reduction in cell surface MHCII levels (Fig. 1C). We also confirmed that the infection of primary human monocytes with WT HIV-1 (Ada strain) led to substantial loss of cell surface MHCII levels, whereas infection with Nef-deleted HIV-1 (Ada) did so only modestly (Fig. 1D, right panel). It is noteworthy that, under the conditions used, the two viruses did not show notable differences in their ability to infect primary human monocytes (Fig. 1D, left panel). Thus, a reduction in cell surface MHCII levels by Nef is relevant for the human monocytic lineage.

To further characterize Nef-mediated down-modulation of MHCII in monocytic cells, we tested some Nef mutants we have previously reported on for their effects on MHCII down-modulation in myeloid cells, using either the human cell line U937 and/or the mouse cell line BMC-2. All findings were consistent between the two cell lines. As expected, the GG to AA mutation of Nef at residues 2 and 3 (G2A), known to be deficient in myristoylation, was unable to down-regulate MHCII or MHCII (Table I). Deletion mutants of Nef truncated from the C terminus to residue 130 continued to show efficient down-modulation of MHCII and MHCII, and while further deletion to residue 105 led to a loss of MHCII down-modulation, this mutant continued to down-modulate MHCII. However, a further deletion to residue 78 led to a loss of...
down-modulation of both MHCI and MHCII (Table I). A clinical isolate of Nef mutated in both the WL57 site and the phosphofructokinase acidic cluster-sorting protein (PACS)-binding E4 site (D1-Nef) (7) also showed a loss of MHCI- and MHCII-down-modulation activity (Table I).

**Nef retards the delivery of MHCII molecules to the plasma membrane**

Previous reports regarding the effects of Nef on cell surface MHCII levels could be interpreted to imply that Nef reduces the rate of MHCII delivery to the cell surface as well as accelerating the removal of cell surface MHCII molecules. We tested both of these possibilities. To test the effect of Nef on the delivery of intracellular MHCII to the cell surface, Nef-expressing U937 cells were stained 12 h after transfection with biotinylated anti-MHCII or anti-CD80 mAbs. They were then either held at 4°C or cultured at 37°C for 2 h. The cells were then stained with the same anti-MHCII or anti-CD80 mAbs conjugated to Cy3-streptavidin to detect the prelabeled molecules, as well as unlabeled CD80 molecules to detect newly expressed molecules. Because the cell surface MHCII and CD80 were saturated with the first round of PE to detect newly expressed molecules. The cell surface MHCII and CD80 were saturated with the first round of mAb binding, no staining was seen with the second round PE-labeled mAbs when the cells had been held at 4°C, showing that no new MHCII or CD80 molecules had arrived at the surface labeled mAbs when the cells had been held at 4°C, showing that mAb binding, no staining was seen with the second round PE-labeled mAbs when the cells had been held at 4°C, showing that no new MHCII or CD80 molecules had arrived at the surface (Fig. 1E). However, if the cells were held at 37°C for 2 h, unlabeled CD80 appeared on the surface and the extent of expression of unlabeled CD80 was not different between eGFP-expressing or Nef-eGFP-expressing cells, indicating that Nef did not affect the rate of exocytosis of CD80 molecules to the cell membrane. In contrast, whereas newly delivered MHCII molecules could indeed be detected in cells held at 37°C, their levels were lower in Nef-expressing cells (Fig. 1E), indicating that Nef retards the delivery of intracellular MHCII molecules to the cell surface.

**Nef relocates cell surface MHCII to intracellular lysosomal compartments**

Nef-mediated internalization of cell surface MHCII was next tracked by the disappearance of MHCII from the cell surface over time in eGFP- or Nef-expressing U937 cells, by labeling surface MHCII with biotinylated mAb and chasing for various times before flow cytometric estimation of surface label loss with fluorophore-labeled streptavidin. To confirm that the label lost from the surface was retained intracellularly, cells were also permeabilized and stained at each chase time point. The data show that in the absence of Nef, MHCII resides stably at the cell surface over an 8-h period, whereas in the presence of Nef MHCII was progressively lost from the surface but remained detectable intracellularly (Fig. 2A). We also tracked the internalization of cell surface MHCII molecules by labeling Nef-transfected U937 cells with fluorochrome-tagged

---

**Table I. Effects of Nef mutations on Nef-mediated down-modulation of cell surface MHCII in monocytic cell lines**

<table>
<thead>
<tr>
<th>Mutants</th>
<th>U937 Human Cells</th>
<th>BMC-2 Mouse Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MHCI</td>
<td>MHCII</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MHCI</td>
</tr>
<tr>
<td>F2-nef (WT)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>F2-nef-G2A</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F2-nef-Δ78</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F2-nef-Δ105</td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td>F2-nef-Δ125</td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td>D1-nef</td>
<td>(+)</td>
<td>(+)</td>
</tr>
</tbody>
</table>

* +, Persistence of down-modulation ability; −, loss of down-modulation ability; (+), weak persistence of down-modulation.

2 MHCII-related data from Ref. 7.

---

**FIGURE 2.** Nef traffics cell surface MHCII to lysosomal compartments. A, U937 cells transfected to express either GFP alone or Nef and eGFP as indicated were surface labeled with anti-MHCII-biotin 12 h after transfection and then cultured for various times as indicated and subjected to the detection of either surface (open symbols) or total (closed symbols) label postpermeabilization. Mean fluorescence intensities were calculated for eGFP-gated cells and the data normalized to the starting intensities as a percentage of the residue of surface-labeled MHCII. The graphs show mean ± SD values of detected fluorescence label calculated from three independent experiments. B, U937 cells transfected to express eGFP (left column) or Nef-eGFP (right column) were surface-labeled 12 h later with anti-MHCII-biotin, and were either stained with labeled streptavidin-Alexa Fluor 568 immediately (0 h; top row) or cultured for 16 h before staining (16 h; bottom row), followed by confocal microscopic imaging. Scale bar, 10 μm. C, U937 cells transfected to express eGFP (left) or Nef-eGFP (right) were fixed 24 h after transfection and stained for MHCII (red; Alexa Fluor 568) and LAMP-1 (blue; Alexa Fluor 647), followed by confocal microscopy. Scale bar, 10 μm. D, U937 cells expressing Nef-eGFP were labeled for MHCII at the cell surface and cultured for various times as indicated. At each time point shown the surface label was stripped and cells were permeabilized and stained for the vesicular marker indicated. For detection of Arf6, U937 cells were cotransfected with plasmids expressing Nef-HA and Arf6-eGFP, and staining include hemagglutinin epitope detection. For tracking colocalization with dextran (Dex) or Tf, cells were given a 10-min pulse with fluorophores, Alexa Fluor 568-Tf or tetramethylrhodamine-Dex 3 h after surface labeling for MHCII. Cells were imaged by either high-resolution, wide-field fluorescence microscopy or confocal microscopy. Images of Nef-expressing cells were quantified for the fraction of internalized MHCII colocalizing with the various markers shown. Data are plotted as the extent of colocalization over time (mean ± SE; n = 100 cells).
anti-MHCII Ab, followed by confocal microscopic examination over time. By 16 h after surface labeling, MHCII molecules had disappeared from the surface of Nef-expressing, but not from control eGFP-expressing U937 cells, and were relocated in intracellular compartments (Fig. 2B).

To identify the intracellular compartment where MHCII was located in Nef-expressing cells, we examined Nef-eGFP-expressing U937 cells for colocalization of MHCII with markers of intracellular compartments by confocal microscopy. Nef-eGFP was colocalized with endogenous MHCII in intracellular organelles marked by the lysosomal marker LAMP-1 (Fig. 2C). Although almost all cell surface MHCII was relocated under the influence of Nef into some LAMP-1-marked compartments, LAMP-1-marked compartments not containing MHCII could also be detected (Fig. 2C), indicating that Nef induced MHCII relocation to specific vesicles within LAMP-1-marked regions.

**Nef redistributes surface MHCII to the lysosomal compartment via endosomal vesicles**

We next examined the colocalization of internalized MHCII in Nef-expressing cells with a range of vesicular and endosomal markers at intermediate stages of internalization to track the pathway of internalization (Fig. 2D). Internalized MHCII molecules in Nef-expressing cells initially colocalized in vesicles bearing Rab5. If the cells were pulsed with either Tf or a fluid-phase marker, tetramethylrhodamine-dextran at appropriate times, initial colocalization was seen with both markers; but whereas Tf was rapidly sorted away from the MHCII, dextran showed stable colocalization. As MHCII-carrying endosomes lost Rab5, they moved into Rab7-bearing compartments from where they began to accumulate stably in LAMP-1-bearing vesicles. No colocalization was seen with either Arf6 or Rab11. These results suggest that, under the influence of Nef, MHCII traffics from early endosomal compartments to lysosomes along with fluid-phase cargo via late endosomal compartments, following the classical pathway of postendocytic progression.

**Molecular mediators of Nef-induced MHCII endocytosis**

We next attempted to identify the molecular intermediates critical for Nef-mediated endocytosis of cell surface MHCII. Because Nef induces both an exocytic blockade and an enhanced endocytosis of MHCII, we distinguished between these two processes in many of the following experiments by using the methodology described above, namely labeling surface MHCII with biotinylated mAb and chasing for various times before flow cytometric estimation of surface label loss with fluorophore-labeled streptavidin. However, detection of cellular levels of MHCII without prior labeling also gave similar results in all instances.

Because MHCII molecules that are being internalized under the influence of Nef first enter compartments marked by the small GTPase Rab5, we examined whether Rab5 was involved in the process of removal. For this, U937 cells were cotransfected with Nef and either WT Rab5 or a DN mutant (S34N) (30) version of Rab5. Cells were stained 36 h later for cell surface MHCII or MHCII. In cells coexpressing Nef with DN Rab5, MHCII internalization was notably reduced whereas MHCII relocation was not blocked (Fig. 3A). Similar data were obtained when cell surface MHCII molecules were prelabeled and chased. The removal of prelabeled MHCII from the surface of Nef-expressing U937 cells was retarded by DN Rab5, and was accelerated by a constitutively active (CA) (30) mutant (Q79L) of Rab5 (Fig. 3B). These data thus implicated Rab5 in the Nef-mediated removal of cell surface MHCII and indicated a difference between the mechanisms of Nef-induced trafficking of cell surface MHCII.

As shown above, Nef-mediated endocytosis of surface MHCII was followed by their delivery from early Rab5-bearing endosomes to late Rab7-bearing endosomes. A protein encoded by the *lyst* gene is known to modulate this trafficking. The beige mouse strain (Bg) harbors a mutation in the *lyst* gene and its cells show reduced sorting to late endosomal compartments (31). Because Nef had similar effects on the removal of surface MHCII in
mouse myeloid cells (Ref. 7 and data above), we used bone marrow-derived monocytes (BMDMs) grown from either WT or Bγ mice and transfected to achieve Nef expression. Nef-expressing Bγ BMDMs showed reduced loss of surface MHCII although MHCI relocation was unaffected (Fig. 3C), again indicating that Nef-mediated removal of MHCII was dependent on the endocytotic trafficking pathway from early to late endosomes.

We (24) and others (32) have previously reported that MHCI removal from the cell surface in Nef-expressing cells is dependent on cholesterol and phosphatidylinositol kinase (PIK) activity. We therefore tested whether MHCII removal in Nef-expressing cells was similarly controlled. Cellular cholesterol was depleted in U937 cells using the cholesterol-chelating agent methyl-β-cyclodextrin (MBCD). MHCII removal from the cell surface was sensitive to MBCD (Fig. 4A) like MHCI removal (24). Low concentrations of wortmannin (Wm), a PIK inhibitor reported to be specific for PI3K (33), did not affect Nef-mediated removal of MHCII whereas a higher concentration retarded it (Fig. 4B), similar to the finding for MHCI removal (24).

Although Nef-mediated CD4 internalization is Dyn dependent, that of MHCI, CD80, or CD86 is not (34). We therefore tested the effect of the DN K44N mutant of Dyn-2 (DN Dyn) (35) or that of a short interfering RNA for Dyn-2 (sh-Dyn) (36) on Nef-mediated MHCII down-modulation in Nef-expressing U937 cells. DN Dyn had no effect on Nef-induced loss of cell surface MHCII (Fig. 4C) or MHCI, CD80, or CD86 as reported earlier (24), although Dyn-dependent Tf endocytosis was blocked as expected (Fig. 4D). Similarly, sh-Dyn did not have any effect on the removal of either MHCI or MHCI in Nef-expressing cells (data not shown). Furthermore, the blockade of molecular activities known to be crucial for the removal of the costimulatory molecules CD80 and CD86 from the surface of Nef-expressing myeloid cells, such as Rac, WASP, TIAM, Src, protein kinase C, or actin (24), had no effect on the reduction of surface MHCII levels in Nef-expressing cells (data not shown).
To assess the role of clathrin in Nef-induced MHCII internalization, U937 cells were cotransfected with Nef and either a DN version of the clathrin adaptor protein Eps15 (95/295) (37) or a DN fragment of another adaptor protein, intersectin (intersectin-A) (38). DN Eps15 and intersectin-A blocked the uptake of Tf as expected (data not shown). In cells coexpressing Nef with DN Eps15 or intersectin-A, MHCII internalization was unaffected while MHC-I relocation was blocked (Figs. 4, E and F), identifying another difference between the Nef-induced trafficking pathways for MHC-I and MHCII.

Together, these data indicate that although mechanisms for cell surface MHC-I and MHCII removal in Nef-expressing cells have some similarities, they differ in their entry into Tf- and fluid phase-marked compartments and in their dependence on clathrin complexes vs Rab5 and Lyst activity.

We also confirmed that the role for Rab5 and the lack of a role for Eps15 in Nef-mediated relocation of MHCII was relevant in primary human monocytes as well. Human primary monocyte cultures were cotransfected to express Nef with either WT Rab5/DN Rab5 or WT Eps15/DN Eps15 as above and stained to assess surface MHCII levels. DN Rab5 blocked Nef-mediated relocation of MHCII whereas DN Eps15 did not (Fig. 4G), confirming that the observations on U937 cells were consistent with those on primary human monocytes.

Cell surface MHCII was sorted to LAMP-1-bearing compartments via Rab7-bearing vesicles in Nef-expressing cells as shown above. The endocytosis of MHCII from the surface in Nef-expressing cells appears to be controlled by Rab5 and Lyst. We therefore examined whether Rab7 was crucial in mediating the Nef-mediated lysosomal delivery of MHCII. U937 cells were cotransfected with Nef and a DN mutant (N125I) version of Rab7. DN Rab7 did not block removal of cell surface MHCII (Fig. 5A). However, although internalized MHCII was relocated to LAMP-1-bearing compartments in Nef-expressing cells carrying WT Rab7, this colocalization was blocked in DN Rab7-expressing cells (Figs. 5B and C), demonstrating that Rab7 is critical for lysosomal delivery of internalized MHCII.

**Endocytic intermediates involved in constitutive turnover of peptide-MHCII complexes**

The data above indicated that Nef-mediated endocytotic removal of cell surface MHCII in both human and mouse myeloid cells was initiated by cholesterol- and PIK-dependent events requiring both Rab5 and Lyst. We next examined whether Nef assembled this de novo pathway for MHCII internalization or whether it subverted an existing pathway in the constitutive turnover of MHCII molecules. For this purpose, we generated specific peptide-MHCII (pMHCII) complexes on the surface of the mouse myeloid cell line BMC-2 and tracked its fate using a mAb specific for this pMHCII complex. A peptide from the endogenous protein H-2E-α (EaS2–68; Eap) binds with high affinity to the H-2Aβ MHCII molecule, and this pMHCII complex is specifically recognized by the Y-Ae mAb (39). Therefore, cell surface pMHCII complexes were generated by pulsing BMC-2 cells with synthetic Eap for 60 min. Pulsed cells were incubated for varying times before being stained with either the pMHCII-specific mAb Y-Ae or the H-2Aβ-specific mAb Y-3P for flow cytometry (Fig. 6A) or were labeled at 4°C with biotinylated Y-Ae or Y-3P and then incubated for varying times at 37°C followed by flow cytometric detection using fluorochrome-coupled streptavidin (Fig. 6B). Y-Ae-binding pMHCII complexes generated on BMC-2 cells were lost rapidly from the cell surface, whereas the total H-2Aβ levels did not show any notable change (Figs. 6, A and B). We then examined whether the molecular intermediates involved in Nef-mediated removal of cell surface MHCII also regulated the specific loss of Y-Ae-binding pMHCII complexes from the cell surface.

For this, BMC-2 cells were pulsed with Eap for 1 h at 37°C and labeled with biotinylated Y-Ae at 4°C as above, followed by incubation for varying times in the presence or absence of MBCD or Wm before the detection of levels remaining at the cell surface. The pMHCII complexes were lost more slowly from the surface if cholesterol was chelated (Fig. 6C). Also, although a low Wm concentration did not affect the rate of removal of pMHCII complexes, a higher concentration, which has been reported to inhibit other PIKs in addition to PI3K (33), also retarded the loss of surface pMHCII (Fig. 6D).

To examine the role of Rab5, BMC-2 cells were transfected with constructs driving the expression of WT Rab5-eGFP, DN Rab5-eGFP, or CA Rab5-eGFP. Cells were pulsed 12 h posttransfection with Eap and labeled with Y-Ae as above and incubated for varying times before the detection of residual surface levels. The pMHCII complexes were lost more slowly from the surface if DN Rab5-expressing cells, while they were lost more rapidly in CA Rab5-expressing cells (Fig. 6E).

We also examined the rate of loss of surface pMHCII complexes from WT and Bg cells. As described above, BMDMs grown from either WT or Bg mice were used. Cells were pulsed with Eap and labeled with Y-Ae as above and the loss of surface label was tracked. Bg BMDMs showed a slower loss of surface pMHCII complexes compared with WT cells (Fig. 6F).

In similar assays, we also examined the effect of blocking molecular activities crucial for Nef-mediated removal of other cell
surface molecules on the rate of pMHCII removal. Blocking the activities of WASP, Dyn, or Eps15 had no effect on the rate of loss of pMHCII complexes from the surface of BMC-2 cells (data not shown).

Together, these data indicate that short-lived pMHCII complexes on mouse monocytic cells, even in the absence of Nef, are removed from the cell surface by an endocytotic mechanism dependent on cholesterol, PIK, Rab5, and Lyst. This concordance between the trafficking pathways of total cell surface MHCII in Nef-expressing cells and those of specific pMHCII complexes in non-Nef-expressing cells suggests that Nef may be subverting constitutive pathways of MHCII endocytosis for the removal of cell surface MHCII molecules.

Discussion

In epithelial cells expressing the CIITA, Nef has been reported to affect MHCII-mediated Ag presentation by altering the intracellular trafficking of MHCII molecules to reduce the levels of mature MHCII and increase immature MHCII on the cell surface (9). Because Ii-associated immature MHCII is functionally incompetent, an immune evasion function has been suggested (9). The delivery of immature MHCII to the lysosomes is also impaired, resulting in reduced Ii degradation (17). However, in the presence of Nef, MHCII is found at high levels in intracellular lysosomal compartments. Our results now extend these findings to professional APCs of the myeloid lineage and identify some molecular intermediates used by Nef to induce surface MHCII down-regulation. We find that this pathway is similar to that used in constitutive endocytosis of peptide-MHCII complexes, indicating that Nef subverts a pre-existing MHCII endocytic program.

Human as well as mouse myeloid cells are sensitive to these effects of Nef, and these observations are consistent between cell lines and primary monocytes of both human and mouse origin. The phenomenon is likely to be of some pathophysiological significance, because Nef-dependent loss of cell surface MHCII is seen on HIV-1 infection, although there are significant differences between the laboratory strain of HIV-1 and clinical isolates, raising the possibility of interesting variations in this property in the latter group. The loss of cell surface MHCII in monocytic cells expressing Nef is not accompanied by any loss of total cellular levels of MHCII, indicating that Nef mediates a cellular redistribution of MHCII. This characteristic is also seen with regard to MHCII,
including our observation of a clinical isolate that is inefficient in the down-modulation of MHCI and MHCII, but not in that of CD80 and CD86.

The removal of cell surface MHCII could be the result of reduced delivery to the cell surface and/or enhanced removal by endocytosis. Unlike the case for MHCI, CD80, and CD86 (Ref. 7 and data not shown), MHCII delivery to the cell surface is retarded in Nef-expressing cells. However, Nef induces endocytic removal of all four of these target molecules. The eventual intracellular destinations of these molecules in Nef-expressing cells, are however, quite distinct. Although MHCI, CD80, and CD86 are removed to the Golgi region, MHCII relocates to the lysosomal compartment.

Similarly, the differences between the vesicular trafficking pathways followed by these target molecules in Nef-expressing cells are different and noteworthy. We observed recently that CD80 and CD86 are internalized into vesicles that do not show any markers of endosomal compartments and that they recruit Rab11 after a lag of some hours, using Rab11 activity for cargo delivery to the Golgi, although Rab11 activity is not required for the Golgi localization of MHCI (40). In contrast, both MHCI (41) and MHCII enter early endosomal compartments marked by Rab5 and either fluid cargo and/or Tf. However, their pathways then diverge. MHCII molecules go on to the sorting compartment marked by Arf6 and then to the Golgi apparatus (41), whereas MHCII molecules move to the late endosomes marked by Rab7 and then to a LAMP-1-bearing lysosomal compartment using Rab7 activity.

Similarly, we find that the molecular intermediates involved in the Nef-mediated endocytosis of these four target molecules show major differences. CD80 and CD86 follow a unique endocytosis pathway defined by its dependence on protein kinase C, c-Src, TIAM, Rac, and actin and by being independent of cholesterol, clathrin, Dyn, and PIK activity (24). In fact, we have not to date found any molecular intermediates shared by CD80/CD86 on the one hand and MHCI/MHCII on the other. However, MHCI and MHCII also show striking differences in the signaling intermediates used for their Nef-mediated endocytosis. Although both are cholesterol- and PIK-dependent and Dyn-independent, MHCI appears to use some form of the clathrin-adaptor complex whereas MHCII does not. Although both enter Rab5-containing vesicles, MHCII endocytosis does not depend on Rab5 or Lyst activity, whereas MHCII endocytosis does.

It is thus possible to argue for a model in which recycling MHCI enters sorting endosomes for a decision on whether they will be recycled back to the cell surface or not, which is where Nef may intervene and reroute them to the Golgi apparatus (41). However, MHCII molecules may recycle through an early endosomal compartment dependent on the homologous fusion of early endosomes controlled by Rab5 so that the lack of Rab5 activity may lead to default delivery to late endosomes and then by normal endolysosomal Rab7-dependent maturation mechanisms to the lysosomes. Because Bg cells show defective trafficking to the late endosomal compartments and increased ability of these lysosomes to fuse with the plasma membrane (42, 43), the loss of Nef-mediated MHCII down-regulation in Bg cells can perhaps be explained either by enhanced recycling back to the cell surface from early endosomes and/or by fusion of Bg lysosomes with the plasma membrane.

Such organized and branching cascades of signaled traffic suggest that Nef may be using pre-existing pathways normally used for the control of trafficking and turnover for these molecules. It is also of interest in this connection to note that, although Nef does bind to the cytosolic tails of CD80 and CD86 directly, evidence regarding its recruitment to the cytoplasmic portions of either MHCI or MHCII is sparse (9, 44), suggesting a possible alteration of normal turnover pathways rather than a directly induced endocytosis. We examined this possibility by testing whether peptide-MHCII complexes on the cell were normally internalized and, if so, whether the signaling intermediates needed for Nef-dependent removal of cell surface MHCII were also involved in the normal removal of pMHCII complexes. Our data indicate that pMHCII complexes are short lived on the cell surface and that their loss is indeed significantly dependent on cholesterol, PIK, Rab5, and Lyst activity.

There is thus a considerable degree of overlap between the molecular intermediates that are involved in the removal of Y-Ae-reactive pMHCII complexes from the APC surface and those involved in the Nef-induced internalization of MHCII molecules. Both endocytic programs are sensitive to cholesterol depletion, require PIK activity, are dependent on Lyst as well as Rab5 function, and intracellular trafficking of the internalized complexes is Rab7 dependent. Thus, Nef appears to subvert a constitutive endocytic program that removes pMHCII complexes from the cell surface to mediate the removal of all MHCII molecules from the cell surface. How does Nef mediate the accelerated removal of MHCII molecules by such a constitutive pathway? In this context, an interesting difference between Nef-mediated MHCII removal and constitutive removal of pMHCII complexes is notable. The constitutive program appears to remove specific pMHCII complexes rapidly from the cell surface over time without affecting the equilibrium MHCII levels, whereas Nef extends this short-lived property to all cell surface MHCII molecules. Nef clearly retards the exocytosis of newly formed MHCII molecules, including their delivery to the endolysosomal compartments (17), and we have observed in preliminary experiments that that inhibition of protein synthesis in normal APCs leads to a rapid loss of pre-existing cell surface MHCII molecules (data not shown). It is thus possible to visualize an intriguingly novel model in which the recycling of MHCII from endosomal compartments is dependent on the availability of new peptide as well as MHCII in those compartments, and their lack leads to a sorting decision in favor of lysosomal delivery. Further studies will be needed to establish the validity and mechanisms of such a process.

Acknowledgments
We are grateful to Drs. Mark McNiven, Alice Dautry-Varsat, Nigel Bunnett, Marino Zerial, Warner Greene, Heinrich Gottlinger, Mario Stevenson, and S. Mahalingam for generously providing reagents. We acknowledge the National Institutes of Health AIDS Reagent Bank for the pNL4-3 molecular clone. We are grateful to Dr. H. Krishnamurthy (National Centre for Biological Sciences (NCBS), Bangalore, India) for his help with the use of the Wellcome Trust-aided Imaging Facility at NCBS.

Disclosures
The authors declare that they have no competing financial interests.

References


Corrections


Two of the line colors were incorrectly identified in the legend for Fig. 1B. The fourth sentence of the legend to Fig. 1 should read as follows: “B, U937 cells were either mock infected (black line) or infected with WT HIV-1 (NL4-3; red line) or with nef-deleted NL4-3 virus (blue line) and stained for cell surface MHCII and intracellular HIV-1 p24 protein 2 days later.”

This error does not change the conclusions of the work or the interpretation of the results.


The fourth author’s name was omitted from the article. The corrected author and affiliation lines are shown below.

Nia Tatsis,* Marcio O. Lasaro,* Shih-Wen Lin,*† Larissa H. Haut,‡ Zhi Q. Xiang,* Dongming Zhou,* Lauren DiMenna,* Hua Li,* Ang Bian,* Sarah Abdulla,* Yan Li,* Wynetta Giles-Davis,* Jessica Engram,* Sarah J. Ratcliffe,* Guido Silvestri,* Hildeguard C. Ertl,* and Michael R. Betts§

*The Wistar Institute, Philadelphia, PA 19104; †University of Pennsylvania School of Medicine, Philadelphia, PA 19104; ‡Departamento de Microbiologia e Parasitologia, Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, Brazil; and §Department of Pathology and Laboratory Medicine, Department of Biostatistics and Epidemiology, and Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104